FGFR2 and cholangiocarcinoma: A multicenter study of 108 patients with the identified fusion FGFR2 gene treated for cholangiocarcinoma in the later stages of the disease found that infigratinib showed an overall response rate of 23.1% with a mean response time (RT) of 5 months and a mean progression-free survival (mPFS) of 7.3 months [24].